cagrilintide phase 3 CagriSema: Phase 3 Results, Dosing,

1):S32S41

Stability Window: When mixed with bacteriostatic water, the solution is generally stable for about 28 to 30 days

Injectable Dose: 0.1 to 0.2 mg three times weekly Topical Option: Apply serum to target areas twice daily Combined Approach: Injectable 3x weekly plus topical to specific areas Duration: 8 to 12 weeks, can extend longer due to favorable safety profile The timing of GHK-Cu introduction matters for maximum benefit

It upregulates vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), stimulates angiogenesis to improve blood supply to damaged tissue, and enhances collagen synthesis at injury sites